(Q35074324)

6 August 2017

1 reference

title

Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting (English)

1 reference

postoperative nausea and vomiting

6 August 2017

main subject

0 references

1 reference

Anthony L Kovac

1

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

26

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

227-259

1 reference

RETRACTED: Prevention of postoperative nausea and vomiting in female patients during menstruation: comparison of droperidol, metoclopramide and granisetron.

6 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200326040-00003

Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.

21 January 2018

1 reference

12 December 2020

Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group

1 reference

12 December 2020

Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy

1 reference

12 December 2020

Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron.

1 reference

12 December 2020

The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control

1 reference

12 December 2020

Optimal dose of granisetron for prophylaxis against postoperative emesis after gynecological surgery.

1 reference

12 December 2020

A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures

1 reference

12 December 2020

Precipitation of ondansetron in alkaline solutions

1 reference

12 December 2020

Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group

1 reference

12 December 2020

The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis

1 reference

12 December 2020

Pharmacokinetics of ondansetron in patients with hepatic insufficiency

1 reference

12 December 2020

The development of tropisetron in its clinical perspective

1 reference

12 December 2020

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy

1 reference

12 December 2020

RETRACTED: Granisetron/dexamethasone combination for reducing nausea and vomiting during and after spinal anesthesia for cesarean section.

1 reference

12 December 2020

Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist

1 reference

12 December 2020

Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers

1 reference

12 December 2020

Single-dose i.v. granisetron in the prevention of postoperative nausea and vomiting.

1 reference

12 December 2020

Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting.

1 reference

12 December 2020

Intravenous ondansetron in established postoperative emesis in children. S3A-381 Study Group.

1 reference

12 December 2020

5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis

1 reference

12 December 2020

Ondansetron: a novel antiemetic agent.

1 reference

12 December 2020

Ondansetron. Therapeutic use as an antiemetic

1 reference

12 December 2020

The role of 5-HT in postoperative nausea and vomiting

1 reference

12 December 2020

RETRACTED: Prophylactic antiemetic therapy with granisetron-dexamethasone combination in women undergoing breast surgery.

1 reference

12 December 2020

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

1 reference

12 December 2020

Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects

1 reference

12 December 2020

RETRACTED: Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting.

1 reference

12 December 2020

Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic

1 reference

12 December 2020

Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects

1 reference

12 December 2020

A survey of postoperative nausea and vomiting

1 reference

12 December 2020

Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting.

1 reference

12 December 2020

Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy

1 reference

12 December 2020

RETRACTED: The effects of dexamethasone on antiemetics in female patients undergoing gynecologic surgery.

1 reference

12 December 2020

Tropisetron. A review of the clinical experience

1 reference

12 December 2020

Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial.

1 reference

12 December 2020

Multiple-dose, placebo-controlled, phase I study of oral dolasetron

1 reference

12 December 2020

The number needed to treat: a clinically useful measure of treatment effect

1 reference

12 December 2020

A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues

1 reference

12 December 2020

A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery.

1 reference

12 December 2020

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery

1 reference

12 December 2020

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

12 December 2020

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

1 reference

12 December 2020

RETRACTED: Reduction of postoperative nausea and vomiting with granisetron.

1 reference

12 December 2020

Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels

1 reference

12 December 2020

Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary

1 reference

12 December 2020

Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment

1 reference

12 December 2020

RETRACTED: Granisetron/dexamethasone combination for the prevention of postoperative nausea and vomiting after thyroidectomy.

1 reference

12 December 2020

A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups

1 reference

12 December 2020

An assessment of clinically useful measures of the consequences of treatment

1 reference

12 December 2020

Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting.

1 reference

12 December 2020

Unanticipated admission to the hospital following ambulatory surgery.

1 reference

12 December 2020

Trials to assess equivalence: the importance of rigorous methods

1 reference

12 December 2020

Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

1 reference

12 December 2020

A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers

1 reference

12 December 2020

Correlation of anti-emetic efficacy and plasma levels of ondansetron

1 reference

12 December 2020

Evidence based medicine: what it is and what it isn't

1 reference

12 December 2020

The effect of three dose levels of ICS 205-930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting.

1 reference

12 December 2020

Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Tropisetron for the prevention of postoperative nausea and vomiting in women undergoing gynecologic surgery.

1 reference

12 December 2020

Recent advances in the management of nausea and vomiting caused by antineoplastic agents

1 reference

12 December 2020

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

1 reference

12 December 2020

Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.

1 reference

12 December 2020

Evaluation of three risk scores to predict postoperative nausea and vomiting.

1 reference

12 December 2020

RETRACTED: Granisetron-dexamethasone combination reduces postoperative nausea and vomiting

1 reference

12 December 2020

5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy

1 reference

12 December 2020

RETRACTED: Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis.

1 reference

12 December 2020

Safety of ondansetron

1 reference

12 December 2020

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children.

1 reference

12 December 2020

RETRACTED: Prevention of postoperative nausea and vomiting with a combination of granisetron and droperidol.

1 reference

12 December 2020

Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist

1 reference

12 December 2020

Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.

1 reference

12 December 2020

The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome

1 reference

12 December 2020

Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.

1 reference

12 December 2020

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

1 reference

12 December 2020

Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review

1 reference

12 December 2020

Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic

1 reference

12 December 2020

Toxicity of chemotherapy

1 reference

12 December 2020

Tropisetron, a new 5-HT3-receptor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhoea

1 reference

12 December 2020

Droperidol/ondansetron combination controls nausea and vomiting after tubal banding.

1 reference

12 December 2020

Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report

1 reference

12 December 2020

A double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of intravenous granisetron in the treatment of postoperative nausea and vomiting in patients undergoing surgery with general anesthesia.

1 reference

12 December 2020

The effect of dexamethasone on postoperative vomiting after tonsillectomy

1 reference

12 December 2020

Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene

1 reference

12 December 2020

Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans

1 reference

12 December 2020

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

1 reference

12 December 2020

Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs, and humans

1 reference

12 December 2020

Droperidol causes a dose-dependent prolongation of the QT interval

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP).

1 reference

12 December 2020

Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.

1 reference

12 December 2020

The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

1 reference

12 December 2020

Pharmacology of serotonin as related to anesthesia

1 reference

12 December 2020

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

12 December 2020

The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting.

1 reference

12 December 2020

Ondansetron does not affect alfentanil-induced ventilatory depression or sedation

1 reference

12 December 2020

Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery.

1 reference

12 December 2020

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron

1 reference

12 December 2020

Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting

1 reference

12 December 2020

Ondansetron and chest pain

1 reference

12 December 2020

Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects

1 reference

12 December 2020

Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group.

1 reference

12 December 2020

Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide

1 reference

12 December 2020

A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers.

1 reference

12 December 2020

Cardiovascular stability with rapid intravenous infusion of ondansetron.

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

1 reference

12 December 2020

Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group

1 reference

12 December 2020

The long QT syndrome. Prospective longitudinal study of 328 families

1 reference

12 December 2020

Postoperative nausea and vomiting in paediatric patients

1 reference

12 December 2020

Preclinical approach for identifying drug interactions

1 reference

12 December 2020

RETRACTED: Granisetron/dexamethasone combination for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy

1 reference

12 December 2020

Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials

1 reference

12 December 2020

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

When placebo controlled trials are essential and equivalence trials are inadequate

1 reference

12 December 2020

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.

1 reference

12 December 2020

Dexamethasone for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomized controlled studies

1 reference

12 December 2020

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.

1 reference

12 December 2020

Tropisetron for treating established postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials

1 reference

12 December 2020

A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda

1 reference

12 December 2020

Effects of granisetron with doxorubicin or epirubicin on ECG intervals

1 reference

12 December 2020

Cardiovascular comorbidity in the older cancer patient.

1 reference

12 December 2020

The anti-emetic efficacy of a combination of ondansetron and droperidol.

1 reference

12 December 2020

Single-dose, placebo-controlled, phase I study of oral dolasetron

1 reference

12 December 2020

Prevention and treatment of postoperative nausea and vomiting

1 reference

12 December 2020

Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting.

1 reference

12 December 2020

Preoperative oral ondansetron for pediatric tonsillectomy.

1 reference

12 December 2020

Hospital admissions from the Surgical Day Care Centre of Vancouver General Hospital 1977-1987.

1 reference

12 December 2020

Meta-analysis of controlled randomized studies on droperidol for prevention of postoperative phase vomiting and nausea

1 reference

12 December 2020

Postoperative nausea and vomiting. Its etiology, treatment, and prevention.

1 reference

12 December 2020

Dexamethasone in combination with dolasetron for prophylaxis in the ambulatory setting: effect on outcome after laparoscopic cholecystectomy

1 reference

12 December 2020

A comparison of three antiemetic combinations for the prevention of postoperative nausea and vomiting.

1 reference

12 December 2020

Can postoperative nausea and vomiting be predicted?

1 reference

12 December 2020

Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting.

1 reference

12 December 2020

Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications

1 reference

12 December 2020

Comorbidity, nutritional intake, social support, weight, and functional status over time in older cancer patients receiving radiotherapy

1 reference

12 December 2020

Cancer burden in the aged: an epidemiologic and demographic overview

1 reference

12 December 2020

RETRACTED: Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness.

1 reference

12 December 2020

RETRACTED: Prophylactic antiemetic therapy with a combination of granisetron and dexamethasone in patients undergoing middle ear surgery

1 reference

12 December 2020

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery

1 reference

12 December 2020

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

RETRACTED: Granisetron/Dexamethasone Combination for Reducing Nausea and Vomiting During and After Spinal Anesthesia for Cesarean Section

1 reference

11 February 2024

https://opencitations.net/index/api/v1/citations/10.1213/00000539-199906000-00028

Identifiers

DOI

10.2165/00002018-200326040-00003

1 reference

Dimensions Publication ID

6 August 2017

1040213313

0 references

1 reference